PresentationsProof of concept of NX-2127, a first-in-class Bruton’s Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with DLBCL By AldenMC Production / June 14, 2023
PresentationsBTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Preclinical Proof of Concept Studies in Intracranial Patient-Derived Model By AldenMC Production / June 14, 2023
PresentationsDrug-resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation By AldenMC Production / June 14, 2023
PresentationsRobust Bruton’s tyrosine kinase (BTK) degradation with NX-5948, an oral BTK degrader, in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies By AldenMC Production / June 14, 2023
PresentationsDeploying Affinity Selection Mass Spectrometry (ASMS) for Rapid and Flexible Hit Confirmation of DNA-Encoded Library (DEL) Screening in Targeted Protein Modulation (TPM) By AldenMC Production / May 31, 2023
PresentationsDiscovery and development of targeted protein modulators for the treatment of hematologic malignancies and solid tumors By AldenMC Production / May 19, 2023
PresentationsExploring Success with Targeting a Novel E3 Ligase with a Small Molecule Inhibitor By AldenMC Production / April 25, 2023
PresentationsFirst Disclosure of NX-2127, an oral targeted degrader of Bruton’s tyrosine kinase (BTK) with concurrent immunomodulatory activity for the treatment of B-cell malignancies By AldenMC Production / April 17, 2023
PresentationsNX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants By AldenMC Production / April 17, 2023
